6o4z: Difference between revisions
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6o4z FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o4z OCA], [https://pdbe.org/6o4z PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6o4z RCSB], [https://www.ebi.ac.uk/pdbsum/6o4z PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6o4z ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6o4z FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o4z OCA], [https://pdbe.org/6o4z PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6o4z RCSB], [https://www.ebi.ac.uk/pdbsum/6o4z PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6o4z ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[https://www.uniprot.org/uniprot/ | [https://www.uniprot.org/uniprot/A0A140T913_HUMAN A0A140T913_HUMAN] | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Latest revision as of 12:08, 9 October 2024
Structure of HLA-A2:01 with peptide MM92Structure of HLA-A2:01 with peptide MM92
Structural highlights
FunctionPublication Abstract from PubMedTargeting CD8(+) T cells to recurrent tumor-specific mutations can profoundly contribute to cancer treatment. Some of these mutations are potential tumor antigens although they can be displayed by non-spliced epitopes only in a few patients, because of the low affinity of the mutated non-spliced peptides for the predominant HLA class I alleles. Here, we describe a pipeline that uses the large sequence variety of proteasome-generated spliced peptides and identifies spliced epitope candidates, which carry the mutations and bind the predominant HLA-I alleles with high affinity. They could be used in adoptive T cell therapy and other anti-cancer immunotherapies for large cohorts of cancer patients. As a proof of principle, the application of this pipeline led to the identification of a KRAS G12V mutation-carrying spliced epitope candidate, which is produced by proteasomes, transported by TAPs and efficiently presented by the most prevalent HLA class I molecules, HLA-A(*)02:01 complexes. An in silico-in vitro Pipeline Identifying an HLA-A(*)02:01(+) KRAS G12V(+) Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients.,Mishto M, Mansurkhodzhaev A, Ying G, Bitra A, Cordfunke RA, Henze S, Paul D, Sidney J, Urlaub H, Neefjes J, Sette A, Zajonc DM, Liepe J Front Immunol. 2019 Nov 15;10:2572. doi: 10.3389/fimmu.2019.02572. eCollection , 2019. PMID:31803176[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||